Psyched: New MO, MA & NY Bills, Oregon’s Psilocybin Services, MDMA Exports, 3D Farm & More
Three More State-Level Psychedelic Bills In The Works: MO, MA And NY
Women’s Footprint In Psychedelics Is Undeniable, Benzinga’s Psychedelics Advisory Council’s Six New Trailblazers
In its capacity as a financial news and media outlet, Benzinga has added six new members to its Psychedelics Advisory Council.
Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer’s Begin
Core One Labs' Akome Partners To Study Next-Gen Psychedelics
EXCLUSIVE: Defining ‘Natural’ Psychedelics, State Regulations & Ayahuasca’s Benefits
(Part three of a three-part series)
See previous stories:
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
Small Pharma, Inc’s Psychedelics For Major Depression Trial Results And Q1 Earnings
Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major Depressive Disorder (MDD).
This Cannabis Company Will Soon Provide Legal Psychedelics-Assisted Therapy
Major cannabis company Kaya Holdings Inc.
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?
Two New Studies On Classical Psychedelics: Grading Ketamine’s Components, Tuning Down Psilocybin Dosing
Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect
Psychedelics Update: MDMA Export, 3D Farm, Recovery Center Reopens, Mushroom Extraction & E-Commerce
Health Canada Oks Clinical-Grade MDMA Export To UK
Life sciences psychedelics company PharmAla Biotech Holdings Inc. and its manufacturing partners received a Health Canada export permit for no less than 300 grams of proprietary MDMA LaNeo.
EXCLUSIVE: Next-Generation Psychedelics, MEAI – How And Why, An Israeli Scientist Explains
(This is part two of a four-part series)
Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction